- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07325617
Suivi de la Littératie et des Connaissances en IA/LLM chez les Patients Externes en Urologie (TALK-U) (TALK-U)
L'étude TALK-U : Suivi des connaissances et de l'utilisation de l'IA/LLM chez les patients urologiques ambulatoires et leur association avec l'anxiété, la satisfaction et la sensibilisation à la santé - Une étude transversale
This study is a one-time, questionnaire-based survey of adults attending a urology outpatient clinic. The investigators will examine whether patients who use AI chat tools based on large language models (LLMs), such as ChatGPT, before seeking care differ from non-users in (1) anxiety, (2) satisfaction with the clinic visit, and (3) awareness/understanding of their health condition.
Participants who provide written informed consent will complete a brief survey during their clinic visit (about 5-7 minutes). The survey includes a standardized anxiety scale (GAD-7), visual analog scales (0-10) for anxiety before and after the visit, satisfaction, and disease awareness, as well as questions about AI/LLM knowledge and use. Treating clinicians will not have access to participants' survey responses, and participation will not affect clinical care.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
The TALK-U study is a cross-sectional, observational survey conducted in the urology outpatient clinic of Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital. The primary exposure is self-reported AI/LLM knowledge and use for health information (e.g., whether participants have used ChatGPT or similar tools, frequency, awareness of AI, and purpose of use). The primary outcome is anxiety measured by GAD-7 at the time of the clinic encounter. Secondary outcomes include (i) anxiety assessed on a 0-10 visual analog scale before and after the visit, (ii) outpatient visit satisfaction (0-10 VAS), and (iii) perceived disease awareness/understanding (0-10 VAS).
Eligible adult first-time urology outpatients who can complete the survey independently and provide informed consent will be invited during a 2-month recruitment period. Analyses will compare outcomes between AI/LLM users and non-users and explore associations with age group (<40, 40-60, >60), education level, and urology subspecialty category. Data will be analyzed using appropriate parametric/nonparametric tests depending on distribution, with p < 0.05 considered statistically significant.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
Yenimahalle/Ankara
-
Ankara, Yenimahalle/Ankara, Turquie (Türkiye), 06200
- Dr.Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Adult patients (≥18 years) presenting for a first-time visit to the Urology Outpatient Clinic at Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital will be invited to participate during a 2-month recruitment period. Participants who provide written informed consent and can complete a brief questionnaire independently will be enrolled. The study will include both sexes and a broad range of urologic presenting complaints.
La description
Inclusion Criteria:
- Age 18 years or older
- First-time visit to the Urology Outpatient Clinic
- Able to read and write and complete the questionnaire independently
- Able to provide written informed consent
Exclusion Criteria:
- Age under 18 years
- Insufficient literacy to understand and complete the questionnaire
- Severe hearing or visual impairment, or a neurological/psychiatric condition that prevents understanding and completing the survey
- Refusal or inability to provide informed consent
- Currently under follow-up for a known urologic condition (i.e., not a first-time urology outpatient visit)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: CASE_CONTROL
- Perspectives temporelles: CROSS_SECTIONAL
Cohortes et interventions
Groupe / Cohorte |
|---|
|
AI/LLM users
Participants who report prior use of AI chat tools based on large language models (e.g., ChatGPT or similar) for health information before the outpatient urology visit, as assessed by the study questionnaire. |
|
non AI/LLM users
Participants who report no prior use of AI/LLM chat tools (e.g., ChatGPT or similar) for health information before the outpatient urology visit, as assessed by the study questionnaire. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Pre-visit Anxiety (VAS 0-10)
Délai: Day 0 (immediately before the outpatient visit)
|
Self-rated anxiety on a 0-10 visual analog scale (VAS), where 0 indicates no anxiety and 10 indicates the highest possible anxiety. This measure reflects visit-related state anxiety prior to clinician encounter. |
Day 0 (immediately before the outpatient visit)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Post-visit Anxiety (VAS 0-10)
Délai: Day 0 (immediately after the outpatient visit)
|
Self-rated anxiety on a 0-10 VAS (0 = none, 10 = highest). |
Day 0 (immediately after the outpatient visit)
|
|
Visit Satisfaction (VAS 0-10)
Délai: Day 0 (immediately after the outpatient visit)
|
Self-rated satisfaction with the outpatient visit on a 0-10 VAS (0 = not satisfied at all, 10 = maximum satisfaction). |
Day 0 (immediately after the outpatient visit)
|
|
Disease Awareness/Understanding (VAS 0-10)
Délai: Day 0 (during the outpatient clinic visit)
|
Self-rated awareness/understanding of one's condition on a 0-10 VAS (0 = none, 10 = complete). |
Day 0 (during the outpatient clinic visit)
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Baseline General Anxiety Symptoms (GAD-7 Total Score)
Délai: Day 0 (at enrollment; prior to or during the clinic visit)
|
Total score on the 7-item GAD-7 questionnaire (range 0-21; higher scores indicate greater generalized anxiety symptoms). This measure will be used to account for baseline anxiety (trait-like symptoms) and to adjust analyses of VAS-based state anxiety out |
Day 0 (at enrollment; prior to or during the clinic visit)
|
Collaborateurs et enquêteurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2025-06/98
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .